Modalis Therapeutics Corporation [4883.T]
TOKYO, Apr 01 (Pulse News Wire) – Modalis Therapeutics Corporation (4883.T) reported the monthly exercise status of its 17th tranche warrant (exercise price adjustment clause attached) allocated to EVO FUND for the month of March 2026. A total of 28,000 warrants were exercised during the month, representing 14.6% of the total issuance of 192,000 warrants.
As of the end of March, there were 37,800 unexercised warrants remaining out of the total issuance. In March, the company delivered shares based on the exercise of warrants on several occasions. On March 5, 1,560,000 shares were transferred against the exercise of 15,600 warrants at an exercise price of ¥54 per share. On March 6, 280,000 shares were transferred against the exercise of 2,800 warrants at an exercise price of ¥56 per share. Additionally, on March 17, 250,000 shares were transferred against the exercise of 2,500 warrants at an exercise price of ¥57 per share.
On March 24, 120,000 shares were transferred against the exercise of 1,200 warrants at an exercise price of ¥56 per share. Lastly, on March 27, 520,000 shares were transferred against the exercise of 5,200 warrants at an exercise price of ¥57 per share. Regarding the exercise limitations based on listing regulations, the combined number of exercisable shares was 2,800,000, while the number of outstanding listed shares was 76,933,798. The exercise ratio, rounded to two decimal places, stood at 3.64%. Details of the warrant issuance can be found in the announcement published on August 7, 2025.
🟢 Confidence: High AI-translated content.